# A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

> **NCT06240689** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 104 (estimated)

## Conditions studied

- Locally Advanced Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06240689
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-25
- **Primary completion:** 2025-01-25
- **Final completion:** 2027-01-05
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06240689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06240689, "A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06240689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*